Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 07, 2022 08:05 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

– Demonstrates statistically significant and clinically meaningful results – – Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse...
April 27, 2021 08:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal

– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy –– Nearly half of trial participants are women, a...
January 09, 2017 08:05 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid

ANN ARBOR, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing complementary oral therapies for...